ClinicalTrials.Veeva

Menu

Study Evaluating Etanercept and Methotrexate in Plaque Psoriasis

Wyeth logo

Wyeth

Status and phase

Completed
Phase 4

Conditions

Psoriasis
Arthritis, Psoriatic

Treatments

Drug: Methotrexate
Drug: Etanercept

Study type

Interventional

Funder types

Industry

Identifiers

NCT00161655
0881A-101696

Details and patient eligibility

About

The purpose of this study is to evaluate the efficacy to clear or almost clear the plaques in plaque psoriasis patients, treated with the combination etanercept and methotrexate compared to etanercept alone.

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Active plaque psoriasis involving >10% body surface area and/or minimal screening PASI score 8.
  • Methotrexate >7.5 mg/week for the last 3 months

Exclusion criteria

  • Predominantly guttate, erythrodermic or pustular psoriasis
  • Other skin conditions than psoriasis

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

Trial contacts and locations

8

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems